1. Price to Sales: 1.56 x sales
As of Friday, September 3rd, Research in Motion had 552 million shares outstanding. The price, as of the same date, was $44.78. (Note: We have used the price of RIM’s NASDAQ listing because the company’s financials are reported in US Dollars) This gave The Company a market capitalization of $24.7 billion. In the trailing four quarters RIM posted sales of $15.74 billion.
2. Cash to Market Cap: 9.47%
As of Q1, 2011 (May 29th, 2010) RIM had a Cash and Short Term Investments position of $2.34 billion. The Company’s Market Capitalization, as of Friday, September 3rd was $24.7 billion.
3. Debt to Market Cap: Zero
As of Q1, 2011 (May 29th, 2010) RIM had no Long Term Debt.
4. Three Year Growth: 72.2%
Revenue was $3.03 million in FY 2007. This grew to $14.9 billion in FY 2010.
5. Enterprise Value to Sales: 1.42 x Sales
RIM’s Enterprise Value is $22.36 billion based on a market capitalization of $24.7 billion, plus Long Term Debt of Zero, minus Cash and Short Term Investments of $2.34 billion. In the trailing four quarters, sales totaled $15.74 billion.
All financial information about RIM is gleaned from
their filings with the System for Electronic Document Analysis and
Retrieval (SEDAR)
All calculations are based on The Company’s closing share price as of
close September 3rd, 2010: $44.78
Sales from trailing four quarters: $15.74 billion
Cash and Short Term Investments as of Q1, 2011 (May 29th, 2010): $2.34 billion
Shares outstanding: 552 million
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]